3. Ware RE, Steinberg MH, Kinney TR. Hydroxyurea: an alternative to transfusion therapy for stroke in sickle cell anemia. Am J Hematol 1995;50:140-143.
4. Bradai M, Abad MT, Pissard S, Lamraoui F, Skopinski L, de Montalembert M. Hydroxyurea can eliminate transfusion requirements in children with severe beta-thalassemia. Blood 2003;102:1529-1530.
5. Marchetti M, Vannucchi AM, Griesshammer M, et al. Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations. Lancet Haematol 2022;9:e301-e311.
6. Antonioli E, Guglielmelli P, Pieri L, et al. Hydroxyurea-related toxicity in 3,411 patients with Ph’-negative MPN. Am J Hematol 2012;87:552-554.
7. DePass LR, Weaver EV. Comparison of teratogenic effects of aspirin and hydroxyurea in the Fischer 344 and Wistar strains. J Toxicol Environ Health 1982;10:297-305.
8. Ferm VH. Severe developmental malformations: malformations induced by urethane and hydroxyurea in the hamster. Arch Pathol 1966;81:174-177.
9. Adlard BP, Dobbing J. Maze learning by adult rats after inhibition of neuronal multiplication in utero. Pediatr Res 1975;9:139-142.
10. Gellen-Dautremer J, Le Jeune S, Receveur MC, Foïs E. Hydroxyurea exposure throughout pregnancy in patients with sickle-cell disease: 4 case reports from European non-interventional, multicentric, prospective Escort-HU study. Blood 2019;134:1027.
15. Alvarez-Larrán A, Kerguelen A, Hernández-Boluda JC, et al. Frequency and prognostic value of resistance/intolerance to hydroxycarbamide in 890 patients with polycythaemia vera. Br J Haematol 2016;172:786-793.
22. Marchioli R, Finazzi G, Specchia G, et al. Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med 2013;368:22-33.
23. Finazzi G, Caruso V, Marchioli R, et al. Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study. Blood 2005;105:2664-2670.